Methscopolamineside effects
methscopolamine bromide 5 MG Oral Tablet
Adverse reactions
The following adverse reactions have been observed, but there is not enough data to support an estimate of frequency.
Cardiovascular: Tachycardia, palpitation.
Allergic: Severe allergic reaction or drug idiosyncrasies including anaphylaxis.
CNS: Headaches, nervousness, mental confusion, drowsiness, dizziness.
Special Senses: Blurred vision, dilation of the pupil, cycloplegia, increased ocular tension, loss of taste.
Renal: Urinary hesitancy and retention.
Gastrointestinal: Nausea, vomiting, constipation, bloated feeling.
Dermatologic: Decreased sweating, urticaria and other dermal manifestations.
Miscellaneous: Xerostomia, weakness, insomnia, impotence, suppression of lactation.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective February 24, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Warnings
In the presence of high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with drug use. Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful. Methscopolamine bromide may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug. With overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective February 24, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Contraindications
Glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Methscopolamine Bromide Tablets, 2.5 mg and 5 mg is contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective February 24, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance